Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease

Lisowska, Anna; Święcki, Przemysław; Knapp, Małgorzata; Gil, Monika; Musiał, Włodzimierz J.; Kamiński, Karol; Hirnle, Tomasz; Tycińska, Agnieszka

doi:10.1016/j.advms.2018.08.017

Cited by 19 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We further identified additional proteins that may be implicated in cardiovascular mortality or morbidity, but have not been linked to AD in the past. For example, IGFBP7 was recently found to be more elevated in patients with MI, and may be a good biomarker of coronary artery disease (CAD) occurrence (41). High serum levels of ALCAM were independently associated with an increased risk of cardiovascular death in acute coronary syndrome (42).…”

Section: Discussionmentioning

confidence: 99%

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers

Olesen

Pavel

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Tape-stripping is a minimally invasive approach for skin sampling that captures the cutaneous immune/barrier abnormalities in atopic dermatitis (AD). However, tape-strips have not been used to evaluate molecular changes with therapeutic targeting. In this study, we sought to characterize the proteomic signature of tape-strips from AD patients, before and after dupilumab therapy. Twenty-six AD patients were treated with every-other-week dupilumab 300 mg for 16 weeks. Tape-strips from lesional and non-lesional skin were collected before and after treatment, and analyzed with the Olink proteomic assay. Using criteria of fold-change>1.5 and FDR < 0.05, 136 proteins significantly decreased after dupilumab treatment, corresponding to an overall mean improvement of 66.2% in the lesional vs. non-lesional AD proteome. Significant decreases after dupilumab were observed in immune markers related to general inflammation (MMP12), Th2 (CCL13/CCL17), Th17/Th22 (IL-12B, CXCL1, S100A12), and innate immunity (IL-6, IL-8, IL-17C), while the Th1 chemokines CXCL9/CXCL10 remained elevated. Proteins related to atherosclerosis/cardiovascular risk (e.g., SELE/Eselectin, IGFBP7, CHIT1/ chitotriosidase-1, AXL) also significantly decreased after treatment. Dupilumab therapy suppressed AD-related immune biomarkers and atherosclerosis/cardiovascular risk proteins. Tape-strip proteomics may be useful for monitoring therapeutic response in real-life settings, clinical trials, and longitudinal studies for AD and beyond.

show abstract

Section: Discussionmentioning

confidence: 99%

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers

Olesen

Pavel

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…According to our previous research, IGFBP7 seems to be a good marker of IHD occurrence—its concentration was significantly higher in patients with coronary lesions than in healthy subjects. However, its levels do not reflect IHD advancement [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

The objective of this study was to determine the associations between insulin-like growth-factor-binding protein 7(IGFBP7) concentrations and concentrations of troponin T(TnT), N-terminal pro-B-type natriuretic peptide(NT-proBNP) and the parameters of kidney function in patients with stable ischemic heart disease(IHD). The IHD group consisted of 88 patients, and the population group comprised 66 subjects without a history of IHD. IGFBP7, TnT and NTproBNP concentrations were measured. The IGFBP7 value was considerably higher in the IHD group (1.76 ± 1 ng/mL vs. 1.43 ± 0.44 ng/mL, respectively, p = 0.019). Additionally, IHD subjects had a significantly higher concentration of TnT and NTproBNP. In both groups there was a significant correlation between IGFBP7 and serum parameters of kidney function (creatinine concentration: population gr. r = 0.45, p < 0.001, IHD gr. r = 0.86, p < 0.0001; urea concentration: population gr. r = 0.51, p < 0.0001, IHD gr. r = 0.71, p < 0.00001). No correlation between IGFBP7 and microalbuminuria or the albumin to creatinine ratio in urine was found. Moreover, there was a significant correlation between IGFBP7 concentration and markers of heart injury/overload-TnT and NT-BNP(r = 0.76, p < 0.001 and r = 0.72, p < 0.001, respectively). Multivariate regression analysis in joint both revealed that the IGFBP7 concentration is independently associated with urea, creatinine and TnT concentrations (R2 for the model 0.76). IHD patients presented significantly higher IGFBP7 concentrations than the population group. Elevated IGFBP7 levels are associated predominantly with markers of kidney function and myocardial damage or overload.

show abstract

“…As to the control group, it was homogeneous like in other studies. 34 , 35 However, values observed in adult patients usually are lower than those in our control subjects 34 , 35 suggesting possible fluctuations of IGFBP7 levels with age. Plasma IGFBP7 values were also high in the model of PWScr p−/m+ mice deleted for Snord116 .…”

Section: Discussionmentioning

confidence: 63%

SNORD116 and growth hormone therapy impact IGFBP7 in Prader–Willi syndrome

Eddiry

Diene

Molinas

et al. 2021

Genetics in Medicine

View full text Add to dashboard Cite

Purpose Prader–Willi syndrome (PWS) is a neurodevelopmental disorder with hypothalamic dysfunction due to deficiency of imprinted genes located on the 15q11-q13 chromosome. Among them, the SNORD116 gene appears critical for the expression of the PWS phenotype. We aimed to clarify the role of SNORD116 in cellular and animal models with regard to growth hormone therapy (GHT), the main approved treatment for PWS. Methods We collected serum and induced pluripotent stem cells (iPSCs) from GH-treated PWS patients to differentiate into dopaminergic neurons, and in parallel used a Snord116 knockout mouse model. We analyzed the expression of factors potentially linked to GH responsiveness. Results We found elevated levels of circulating IGFBP7 in naive PWS patients, with IGFBP7 levels normalizing under GHT. We found elevated IGFBP7 levels in the brains of Snord116 knockout mice and in iPSC-derived neurons from a SNORD116-deleted PWS patient. High circulating levels of IGFBP7 in PWS patients may result from both increased IGFBP7 expression and decreased IGFBP7 cleavage, by downregulation of the proconvertase PC1. Conclusion SNORD116 deletion affects IGFBP7 levels, while IGFBP7 decreases under GHT in PWS patients. Modulation of the IGFBP7 level, which interacts with IGF1, has implications in the pathophysiology and management of PWS under GHT.

show abstract

Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease

Cited by 19 publications

References 17 publications

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers

IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart Disease

SNORD116 and growth hormone therapy impact IGFBP7 in Prader–Willi syndrome

Contact Info

Product

Resources

About